文献速递自身免疫性与大疱性皮肤病

成败之间:天疱疮及其他B细胞介导自身免疫病的临床试验

Boom or Bust: Clinical Trials in Pemphigus and Other B-Cell-Mediated Autoimmune Diseases.
PubMed 文献 · J Invest Dermatol · 2025-11-03

本文综述了利妥昔单抗、efgartigimod和rilzabrutinib在B细胞介导自身免疫病中的成功与失败经验。通过比较试验设计和终点,识别影响临床结局的关键问题,以指导天疱疮等疾病的未来临床试验。

要点

  • 利妥昔单抗在天疱疮中成功,但在其他B细胞介导疾病中未重现。
  • efgartigimod和rilzabrutinib在天疱疮中未获批准,尽管在其他抗体介导疾病中有效。
  • 试验设计和终点的差异是影响临床结局的关键因素。

核心结论

  • 天疱疮临床试验的成败与试验设计和终点选择密切相关。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • 利妥昔单抗和泼尼松已获批用于天疱疮,但efgartigimod和rilzabrutinib未获批准。
  • 利妥昔单抗在其他B细胞介导自身免疫病中的成功未能重现。

临床怎么用

  • 应关注试验设计和终点选择对天疱疮临床试验结果的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pemphigus vulgaris (PV) is a B-cell-mediated autoimmune blistering disease characterized by autoantibodies targeting skin cell adhesion proteins. Despite the well-defined pathophysiology and unmet need for safe and effective therapies for pemphigus, multiple therapeutics have failed to advance through clinical development. Prednisone and rituximab are clinically approved for PV, but the neonatal Fc receptor inhibitor efgartigimod and Bruton's tyrosine kinase inhibitor rilzabrutinib failed to receive clinical approval in pemphigus, despite success in other autoantibody-mediated diseases. Conversely, the success of rituximab for PV has not been reproduced for several other B cell-mediated autoimmune diseases. We review learnings from the successes and failures of rituximab, efgartigimod, and rilzabrutinib across B-cell-mediated autoimmune diseases and compare trial designs and endpoints to identify key issues affecting clinical outcomes.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Rujitharanawong C, Werth VP, Payne AS, et al. Boom or Bust: Clinical Trials in Pemphigus and Other B-Cell-Mediated Autoimmune Diseases. J Invest Dermatol. 2025. PMID: 41182210. doi:10.1016/j.jid.2025.09.373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。